Filing of Form 10-Q

MaxCyte announces filing of Form 10-Q for the quarterly period ended March 31, 2024

ROCKVILLE, MD, May 8, 2024- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, announced that it has filed a Form 10-Q with the SEC for the quarterly period ended March 31, 2024. The Company has also filed a Form 8-K with the SEC related to updates to the information contained in their corporate deck.

A copy of the Form 10-Q and Form 8-K are available to view on the SEC's website atwww.sec.govand have also been posted to the "SEC filings" page of the Company's website,https://investors.maxcyte.com/.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more atmaxcyte.comand follow us onXandLinkedIn.

MaxCyte Contacts: